UOC
CRL icon

UBS O'Connor’s Charles River Laboratories CRL Stock Holding History

UBS O'Connor’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,034
Closed -$481K – 536
2023
Q4 		$481K Sell
2,034
-1,177
-37% -$231K 0.02% 355
2023
Q3 		$629K Hold
3,211
– – 0.01% 376
2023
Q2 		$675K Buy
3,211
+158
+5% +$31.4K 0.01% 420
2023
Q1 		$616K Sell
3,053
-3,121
-51% -$707K 0.01% 447
2022
Q4 		$1.34M Buy
+6,174
New +$1.35M 0.02% 533
2015
Q1 		– Sell
-3,440
Closed -$219K – 777
2014
Q4 		$219K Buy
+3,440
New +$216K ﹤0.01% 593

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

UBS O'Connor's CRL Position: Q1 2024 in Review

UBS O'Connor sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 2,034 shares — an estimated $481K sold.

UBS O'Connor first reported a position in CRL in Q4 2014 and held it in 6 quarters. The position peaked at $1.34M in Q4 2022. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • UBS O'Connor reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • UBS O'Connor sold 2,034 Charles River Laboratories shares in Q1 2024, an estimated $481K.
  • UBS O'Connor first reported a position in Charles River Laboratories in Q4 2014 and held it in 6 quarters.
  • UBS O'Connor's Charles River Laboratories position peaked at $1.34M in Q4 2022.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on UBS O'Connor's 13F filing for Q1 2024, filed 15 May 2024.